Emisphere Technologies, Inc. Receives Notice of Results From Collaborator's Proof of Concept Study for Oral PTH for the Treatment of Postmenopausal Osteoporosis

CEDAR KNOLLS, N.J., June 17, 2011 (GLOBE NEWSWIRE) -- Emisphere Technologies, Inc. (OTCQB:EMIS) announced today that Novartis informed Emisphere of the results of its recently completed Proof of Concept study for an oral PTH1-34 using Emisphere's Eligen® Technology in post-menopausal women with osteoporosis or osteopenia. Novartis informed Emisphere that, although the study confirmed that oral PTH1-34 was both safe and well-tolerated, several clinical endpoints were not met. Based on the data analyzed, Novartis has terminated the study and anticipates no further work on the oral formulation of PTH1-34.